---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122824"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:42:38.259752+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences Q3 net loss $18.1M; cash $277M funds into mid-2027; IPO raised $251M

## Summary
- Net loss for Q3 2024 was $18.1M vs $10.2M in Q3 2023; R&D spend rose to $16.7M from $9.1M.
- Cash, equivalents and marketable securities $277.1M as of Sep 30, 2024 (up from $80.7M at Dec 31, 2023).
- IPO and Series C gross proceeds totaled approximately $251.2M.
- Phase 1 trial of MBX 1416 (post-bariatric hypoglycemia) last subject visit by late Nov 2024; topline results early Jan 2025.
- Phase 2 Avail trial of MBX 2109 (hypoparathyroidism) enrollment completion expected Q1 2025; topline results Q3 2025.

## SEC filing metadata
- accession: 0000950170-24-122824
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000095017024122824/0000950170-24-122824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000095017024122824/mbx-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122824
- JSON: https://secwatch.observer/filing/0000950170-24-122824.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.